Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

By sjmartinez • July 16, 2024

Paik JJ, Vencovský J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN Jr, Aggarwal R. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. doi: 10.55563/clinexprheumatol/eeglsa. Epub ahead of print. PMID: 39008325.

Tags: Publications, Rheumatology

Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS)

Blanco LR, Hays RD. Evaluation of the Reliability and Validity of the Retirement Knowledge Scale (RKS). J Retire. 2024 Fall;12(2):76-94. doi: 10.3905/jor.2024.1.164. Epub 2024 Oct[...]

Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease

Ko M, Barai R, Brent G. Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease. Cureus. 2024 Oct 15;16(10):e71551. doi: 10.7759/cureus.71551.[...]

Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey

Armstrong A, Levit NA, Schneider B, Seiden R, Shi L, Kaplan B, Wu JJ. Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient[...]